BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 van der Gracht E, Zahner S, Kronenberg M. When Insult Is Added to Injury: Cross Talk between ILCs and Intestinal Epithelium in IBD. Mediators Inflamm 2016;2016:9765238. [PMID: 27578924 DOI: 10.1155/2016/9765238] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
2 van den Bemt BJF, Gettings L, Domańska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv 2019;26:384-92. [PMID: 30905213 DOI: 10.1080/10717544.2019.1587043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
3 Pouls BPH, Kristensen LE, Petersson M, van den Bemt BJF, Ballerini L, Bruggraber R, Karlen H, Mountian I, van Bracht E, Wiegratz S, Jørgensen TS. A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol. Expert Opin Drug Deliv 2020;17:705-11. [PMID: 32154740 DOI: 10.1080/17425247.2020.1736552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]